Alexander Schuth is Chief Operating and Financial Officer of Denali Therapeutics responsible for finance, corporate development, and portfolio management. He is a co-founder of the company and has served as the COO and Secretary since 2015 and assumed responsibility for the Finance group in 2022.
Alex and his team are working to build, advance and manage a broad portfolio of therapeutic drug candidates and have established over 30 collaborations with partners in industry and academia to accelerate the discovery, development, and eventual commercialization of medicines for neurodegenerative diseases. In addition, Alex has been working with the finance team on all financing and investor relations activities.
Alex previously held operating and leadership positions in the business development and finance groups at Genentech and the investment banking group at Merrill Lynch in London. He holds an M.D. degree from the Charite Medical School at the Humboldt University in Berlin, Germany, and an M.B.A. from the Wharton School of the University of Pennsylvania.